new YORK (Reuters Health) – the application of a

subcutaneous injection of golimumab per month reduced symptoms of

psoriatic arthritis active for a year in an extension

the GO-REVEAL test six months.

In addition to “significant structural damage inhibition”

registered in the week 24, the new data show that the

patients had “maintenance of radiographic benefits and

“”

best physical functions a year”, reported the

in Arthritis & Rheumatism team.

After the 24th week, patients who began to take

placebo were crossed with those used 50 milligrams of

Golimumab, while those with an inadequate response

they received an increase in dose, according to Dr. Arthur

Kavanaugh, of the University of California, San Diego, in the

Jolla.

In week 52, 358 405 original volunteers (the

88 per cent) still taking the drug, they indicated the

authors.

Until the 24th week x-rays showed inhibition of damage

structural in patients treated with golimumab, added

the authors.

The study was funded by Janssen, who sells the drug

monthly subcutaneous golimumab name Simponi. The

Active psoriatic arthritis patients can take Simponi

alone or with methotrexate.

The prospectus information includes a warning that

says that “serious infections leading to international or

“

deaths, including tuberculosis, bacterial sepsis, fungi

invasive (such as histoplasmosis), and other opportunistic infections

“

have occurred in patients taking Simponi”.

Are also advised to patients that they are controlled by

the risk of tuberculosis. Moreover, the warning States that

“reported lymphomas and other malignancies, some

fatal in patients children and adolescents treated with

blockers TNF, Simponi is a member of which”.

In GO-REVEAL, the most common when taking adverse effects

golimumab were upper respiratory tract infections and

nasofaringitis. Fourteen patients treated with the drug (4

per cent) left the trial by a negative event,

reported by the team of Dr. Kavanaugh.

. In conclusion, he said that “the efficacy of golimumab was not

“

substantially different between patients receiving 50

milligrams and those who took 100 milligrams and was comparable to

the observed with other agents available anti-TNF

commercially. “The safety of golimumab was also

consistent with both dose and other agents anti-TNF”.

Source: Arthritis Rheumatism online February 29 2012.